Jobs / United States / Astrazeneca Pharmaceuticals Lp
Senior Director, US Head Country Operations Management, Study Start-up & Site Partnership
Astrazeneca Pharmaceuticals Lp · 🇺🇸 US - Boston - MA
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Astrazeneca Pharmaceuticals Lp paid sponsored hires in similar roles1 certified filing for “Associate Director, Oncology Portfolio Analytics” (Management Analysts) in MD: $157k–$157k, median $157k. Most were filed at wage level II (100%) — 2 lottery entries, ≈31% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Astrazeneca Pharmaceuticals Lp
The US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Astrazeneca Pharmaceuticals Lp →
About the role
Job Title: Senior Director US Head of Country Operations, Study Start-up & Site Partnerships Location: Boston, MA At AstraZeneca, we pride ourselves on crafting a collaborative culture that champions knowledge-sharing, ambitious thinking and innovation – ultimately providing employees with the opportunity to work across teams, functions and even the globe. Recognizing the importance of individualized flexibility, our ways of working allow employees to balance personal and work commitments while ensuring we continue to create a strong culture of collaboration and teamwork by engaging face-to-face in our offices 3 days a week . Our head office is purposely designed with collaboration in mind, providing space where teams can come together to strategize, brainstorm and connect on key projects. Introduction to Role: The Senior Director, US Head of Country Operations, Study Start-up & Site Partnerships will lead the US operating model and end-to-end delivery of clinical studies—from early indication planning and feasibility through site selection, start-up, enrollment, data delivery, and close-out. You will set strategy and priorities, proactively manage risks, and drive performance to deliver programs on or ahead of schedule, within budget, and in compliance with SOPs, ICH/GCP, and US regulations. You will build and develop high-performing leadership and country operations teams, align resources with portfolio needs, and foster a collaborative “One Alexion” culture with sites and institutions. Working across R&D, Medical, Commercial, and other key functions, you will advance portfolio goals, expand US patient participation and trial diversity, and embed innovation, including AI and advanced analytics, into country operations. As the primary escalation point for the US, you will communicate risks and action plans transparently to regional and global COM leadership and contribute to broader priorities. As a key member of the Regional and Global extended COM Leadership Team and the US affiliate extended leadership team, you will strengthen collaboration, visibility, and shared accountability across the organization. This role requires strategic and operational leadership, sound decision-making, and the ability to translate complex market, scientific, regulatory, and performance insights into data-informed strategies that support sustainable growth. Accountabilities: • Own and govern the US Country Operations model, including standards, processes, decision rights, resources, and ways of working aligned with portfolio priorities. • Lead a Country Operations team of 65+ employees, building an inclusive, high-performing culture that strengthens leadership capability, collaboration, accountability, and global patient contribution. • Direct end-to-end study delivery—from indication planning and feasibility through site selection, start-up, enrollment, data delivery, and close-out—to achieve timeline, budget, quality, and country commitments. • Drive US enrollment and clinical trial diversity targets in alignment with the Clinical Trial Diversity Action Plan. • Serve as the primary decision-maker and escalation point for US operations, proactively identifying risks, removing barriers, and communicating mitigation plans to the RHCO and VP, Global COM. • Lead Study Start-up excellence, including contracting, budgeting, EC submissions, and site selection in partnership with Clinical Development and Medical Affairs, to improve cycle times and delivery reliability. • Oversee the US institutional and site alliance strategy, including the Partner in Care Network, and strengthen relationships through consistent engagement, in-person site visits, clear action plans, and a “One Alexion” approach. • Develop innovative site solutions a